VERA logo

Vera Therapeutics Inc. (VERA)

$26.20

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VERA

Market cap

$1.89B

EPS

-5.9

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.059309

Price on VERA

Previous close

$26.97

Today's open

$27

Day's range

$25.82 - $27

52 week range

$25.82 - $56.05

Profile about VERA

CEO

Marshall Fordyce

Employees

361

Headquarters

Brisbane, CA

Exchange

NASDAQ Global Market

Shares outstanding

72298770

Issue type

Common Stock

VERA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VERA

Vera Therapeutics Q3 Earnings Call Highlights

Vera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.

news source

MarketBeat • Nov 6, 2026

news preview

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 14,900 shares of Class A common stock and restricted stock units (RSUs) underlying 7,450 shares of Class A common stock to three (3) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

news source

GlobeNewsWire • Nov 6, 2026

news preview

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3. ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the opening plenary session at ASN Kidney Week 2026 with a simultaneous publication in The New England Journal of Medicine.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates

Vera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, which is taking place in Boston, MA from November 9-11, 2026.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology's Kidney Week meeting in Denver, alongside publication in The New England Journal of Medicine.

news source

MarketBeat • Oct 23, 2026

news preview

Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript

news source

Seeking Alpha • Oct 22, 2026

news preview

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events. Favorable safety profile, and generally comparable to placebo.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026 Q3 2026 financial results investor webcast scheduled at 4:30 p.m.

news source

GlobeNewsWire • Oct 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Vera Therapeutics Inc.

Open an M1 investment account to buy and sell Vera Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VERA on M1